110 Multiparameter tissue imaging reveals the cutaneous T cell lymphoma microenvironment in response to immunotherapy

Cutaneous T cell lymphoma (CTCL) is a devastating malignancy of the skin for which the standard treatments are suboptimal. Immunotherapy is a new treatment paradigm, and two promising agents for CTCL include brentuximab (anti-CD30) and pembrolizumab (anti-PD-1). While clinical trials have shown that many CTCL patients achieve durable responses on these treatments, for unclear reasons about one third of patients experience rapidly progressive disease. Given the potential for negative outcomes and the high costs of immunotherapy, it is critical to find predictive biomarkers that enable stratification of CTCL patients into responders and non-responders prior to initiating immunotherapy.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Carcinogenesis and Cancer Genetics Source Type: research